SCHEMBL4848445

SCHEMBL4848445

CCOP(=O)(/C=C\c1cn(-c2ccccc2)nc1OCc1ccc(OCc2nc(-c3cccc(C(=O)O)c3)oc2C)c(OC)c1)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.40
PPARA Q07869 7/20 0.40
MAPT P10636 4/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
KDR P35968 1/20 0.36
VDR P11473 1/20 0.35
FFAR1 O14842 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
NSD2 O96028 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
HSP90AA1 P07900 1/20 0.35
THRB P10828 1/20 0.35
PKM P14618 1/20 0.35
APEX1 P27695 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843850 1.00 PPARG (0.40) PPARGPPARAMAPTMRGPRX4KDR
SCHEMBL4843835 1.00 PPARG (0.40) PPARGPPARAMAPTMRGPRX4KDR
SCHEMBL4849075 0.95 MAPT (0.38) PPARGPPARAMAPTKDRVDR
SCHEMBL4849080 0.95 MAPT (0.38) PPARGPPARAMAPTKDRVDR
SCHEMBL4851609 0.95 MAPT (0.38) PPARGPPARAMAPTKDRVDR
SCHEMBL4845278 0.94 MAPT (0.43) PPARGPPARAMAPTPOLB
SCHEMBL4845285 0.94 MAPT (0.43) PPARGPPARAMAPTPOLB
SCHEMBL4850483 0.92 PPARG (0.40) PPARGPPARAMAPTKDM4EALDH1A1
SCHEMBL4850472 0.92 PPARG (0.40) PPARGPPARAMAPTKDM4EALDH1A1
SCHEMBL4843642 0.92 PPARG (0.39) PPARGPPARAMAPTKDRFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885PPARA 519/4885MAPT 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.